Lucid News
Lawmakers in the Washington State Legislature have been weighing two distinct and often conflicting visions for the future of legal psychedelics, with the debate intensifying last week as one prominently-backed piece of legislation stalled out in the state’s Ways and Means Committee.
At the center of the controversy is Senate Bill 5921, also known as the Washington Medical Psilocybin Act. While proponents argue it provides necessary clinical guardrails for vulnerable patients, grassroots organizations like Responsible Entheogen Access & Community Healing Coalition (REACH) Washington warn that without concurrent decriminalization for personal use, the state risks creating a “two-tiered system” that favors a medicalized approach that could limit access.
The struggle in Washington reflects a national debate over how to integrate ancient medicines into modern law. SB 5921 treats psilocybin as a pharmaceutical intervention requiring strict Department of Health oversight. In contrast, a pair of bills backed by REACH WA and other grassroots coalition partners – Senate Bill 5201 and House Bill1433 – treats psilocybin more like a regulated craft product under the LCB.
The Clinical Vision: SB 5921 and the Medical Model
Senate Bill 5921 seeks to establish a medical pathway for psilocybin treatment, specifically targeting individuals with complex needs and treatment-resistant conditions. The bill mandates a structured care model, including required preparation and integration sessions, which supporters say ensures patient safety and continuity of care.
The proposal includes several features designed to integrate psychedelics into the existing healthcare infrastructure. It offers an outpatient microdosing option and creates a framework that may allow for insurance coverage under certain conditions. Furthermore, the bill emphasizes data collection and clinical research, aiming to build a more robust evidence base for psychedelic-assisted therapy.
During public testimony on Tuesday January 27, medical professionals highlighted the life-saving potential of the bill. Joy Laramie, a psychiatric nurse practitioner specializing in eating disorders, shared her experience with the University of Washington’s state-funded clinical trials.
“Early research indicates that when properly used, psilocybin is relatively low risk while holding immense promise for those who have failed standard care for anorexia nervosa, PTSD, depression, and other difficult-to-treat conditions,” Laramie testified. She noted that for families dealing with conditions like anorexia – which has a higher mortality rate than any psychiatric illness except opioid addiction – a regulated pathway is not just a luxury, but a necessity.
Brian Kennedy, a private psychotherapist with 30 years of experience in Olympia, echoed this sentiment. Having helped draft the state’s Mental Health Licensure Law, Kennedy described SB 5921 as a “cautious” and “mark-hitting” approach.
“People with serious, often treatment-resistant conditions are already seeking psychedelic interventions, frequently outside regulated medical or therapeutic frameworks,” Kennedy said. “The state is better served by creating guardrails than by ignoring that reality.”
While members of the Senate Health & Long-Term Care Committee advanced SB 5921 to the Ways and Means Committee during a hearing on Feb. 4,– the bill failed to move forward prior to the state’s formal deadline last week, effectively killing the Washington Medical Psilocybin Act for at least another year.
Regulatory Hurdles and Accessibility Concerns
Regardless of the bill’s future, SB 5921 faced significant criticism from advocates who view its medicalized approach as overly restrictive. The bill requires a “qualifying diagnosis,” which critics argue reinforces a narrow clinical model that treats psychedelic use purely as an intervention to “fix” individuals rather than a tool for well-being or cultural practice.
REACH Washington has raised concerns regarding the bill’s extensive regulatory requirements. The proposed auditing, testing, and record-keeping mandates are expected to be costly. Advocates fear these high barriers to entry will incentivize the creation of high-volume psilocybin “mills,” where practitioner caseloads are maximized to cover overhead costs – a pattern that some advocates say has been previously observed in medical cannabis programs.
Read the full article
Varying Approaches to Psychedelic Policy Reform in Washington State
